Metastatic pheochromocytoma and paraganglioma: focus on therapeutics

• Published in: Hormone and metabolic research Vol. 44; no. 5; p. 390
• Main Authors: Plouin, P-F, Fitzgerald, P, Rich, T, Ayala-Ramirez, M, Perrier, N D, Baudin, E, Jimenez, C
• Format: Journal Article
• Language: English
• Published: Germany 01.05.2012
• Subjects: Adrenal Gland Neoplasms - genetics; Adrenal Gland Neoplasms - radiotherapy; Adrenal Gland Neoplasms - surgery; Adrenal Gland Neoplasms - therapy; Animals; Humans; Molecular Targeted Therapy; Neoplasm Metastasis; Paraganglioma - genetics; Paraganglioma - radiotherapy; Paraganglioma - surgery; Paraganglioma - therapy; Pheochromocytoma - genetics; Pheochromocytoma - radiotherapy; Pheochromocytoma - surgery; Pheochromocytoma - therapy
• ISSN: 1439-4286
• DOI: 10.1055/s-0031-1299707

Metastatic pheochromocytomas and paragangliomas are rare and challenging tumors. The tumor burden, combined with excessive catecholamine production, predispose to a broad spectrum of complications that range from spinal cord compression to any organ damage, all of which may lead to decreased quality of life and overall survival. Current therapies include surgery, systemic chemotherapy and radiopharmaceutical agents. Surgery is often a preferred therapy because it may cure or allow a long-term remission in patients with locoregional or isolated resectable distant metastases. Additionally, surgery can palliate symptoms related to tumor burden or catecholamine excess. However, in patients for whom surgery is not an option, systemic chemotherapy and radiopharmaceutical agents are preferred options. Systemic chemotherapy and radiopharmaceutical agents such as 131I-Metaiodobenzylguanidine (131I-MIBG) may cause partial responses or stabilization of disease with better blood pressure control and symptomatic and performance status improvement. However, as these therapies are only palliative, patients' quality of life and personal preferences should always be considered. The recognition of molecular pathways involved in the pheochromocytoma and paraganglioma tumorigenesis has driven the development of new therapeutic options. Agents such as tyrosine kinase, MAPK, PI3K, or hypoxia inducible factor inhibitors, alone or in combination, may represent novel therapeutic strategies that could be evaluated in prospective clinical trials. Transcriptional profiling and the development of personalized cancer medicine will help to pave the way for more specific therapeutic approaches and combinations.